GRAL - NASDAQ
GRAIL, Inc.
$66.93
+9.5%GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
At a Glance
Live SnapshotGRAIL, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
GRAIL, Inc. Income Statement
GRAL • NASDAQ
| GRAIL, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
147.2M | 125.6M | 93.1M | 55.6M | 14.6M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(209.7M) | (203.6M) | (188.7M) | (172M) | (114.6M) | (0.0) | (0.0) | (0.0) | |
-62.6M | -78M | -95.6M | -116.4M | -100M | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||
(471.6M) | (2.1B) | (1.4B) | (5.3B) | (1.2B) | (316.4M) | (255.7M) | (287.5M) | |
(275.8M) | (367.8M) | (362.6M) | (296.4M) | (234.1M) | (123.5M) | (88.6M) | (64.3M) | |
(195.8M) | (322.4M) | (338.7M) | (329.6M) | (460.2M) | (192.9M) | (167.1M) | (223.2M) | |
-534.2M | -2.2B | -1.5B | -5.4B | -1.3B | -316.4M | -255.7M | -287.5M | |
PRE-TAX INCOME | ||||||||
28.7M | 26.7M | 8M | 1.7M | 332K | 6.1M | 12.4M | 8.3M | |
(0.0) | (1.4B) | (718.5M) | (4.7B) | (471.1M) | (0.0) | (0.0) | (0.0) | |
-341K | 26.8M | 7.7M | 1.5M | 90K | 4.3M | 10.6M | 12.3M | |
-534.5M | -2.2B | -1.5B | -5.4B | -1.3B | -312.1M | -245.1M | -275.2M | |
NET INCOME | ||||||||
-126.2M | -135.4M | -42M | -42.3M | -17.5M | (33K) | -195K | (485K) | |
-408.4M | -2B | -1.5B | -5.4B | -1.2B | -312.2M | -244.9M | -275.7M |
SEC Filings
GRAL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your GRAL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.